NT-proBNP as a Diagnostic Marker in CCF

By Dr. Hitesh M R & Dr. Vedavathi R
Kempegowda Institute of Medical Sciences, Bangalore

Introduction-

- Heart failure prevalence is raising throughout the world.
- The overall prevalence of HF is thought to be increasing because current therapies for cardiac disorders, such as Myocardial Infarction (MI), Valvular Heart Disease, and Arrhythmias, are allowing patients to survive longer.
- American Heart Association (AHA) guidelines define HF as a “Complex clinical syndrome that results from structural or functional impairment of ventricular filling or ejection of blood, which in turn leads to the cardinal clinical symptoms of dyspnea and fatigue and signs of HF namely edema and rales”.
- Making the correct diagnosis in patients with Suspected Acute Heart Failure is challenging, and confirmatory in only 40-50% of Cases.
- Several Studies have shown that when added to routine history, Clinical Examination and Conventional investigations measurement of plasma natriuretic peptide levels improve diagnostic accuracy.
- B-type natriuretic peptides (BNP) that are synthesized by the left and right atria in response to cardiomyocyte stretching.
- The human BNP gene encodes a 108 amino acid pro hormone named proBNP.

GJMR-B Classification: NLMC Code: WB 330

© 2016. Dr. Hitesh M R & Dr. Vedavathi R. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License http://creativecommons.org/licenses/by-nc/3.0/, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
NT-proBNP as a Diagnostic Marker in CCF

Dr. Hitesh M R & Dr. Vedavathi R

I. INTRODUCTION

- Heart failure prevalence is raising throughout the world.
- The overall prevalence of HF is thought to be increasing because current therapies for cardiac disorders, such as Myocardial Infarction (MI), Valvular Heart Disease, and Arrhythmias, are allowing patients to survive longer.
- American Heart Association (AHA) guidelines define HF as a “Complex clinical syndrome that results from structural or functional impairment of ventricular filling or ejection of blood, which in turn leads to the cardinal clinical symptoms of dyspnea and fatigue and signs of HF namely edema and rales”.
- Making the correct diagnosis in patients with Suspected Acute Heart Failure is challenging, and confirmatory in only 40-50% of Cases.
- Several Studies have shown that when added to routine history, Clinical Examination and Conventional investigations measurement of plasma natriuretic peptide levels improve diagnostic accuracy.

II. MATERIALS AND METHODS

- The study was conducted on 60 patients between the age group of 40-70 years attending the inpatient and outpatient clinic at Kempegowda Institute of Medical Sciences, Bangalore.
- It was a case control comparative study of 60 patients (30 cases and 30 controls) during the study period from November 2013 to October 2015.
- Informed consent was obtained from all patients /care takers of the patients enrolled for the study.
- The data of the patients was collected in a well designed platform.
- Relevant data about diabetes mellitus, hypertension and Renal disease was taken in the history.
- CBC, Urine Microscopy, RFT, LFT, RBS, Serum Electrolytes, Lipid profile, ECG, Chest X-RAY and 2D Echocardiography was done for all patients.
- Serum NT-proBNP levels were measured by ELFA (Enzyme linked fluorescence Assay) technique.
- Cases: Patients suspected to have heart failure based on history, Clinical examination and ECG (Age and Sex Matched individuals).
- Controls: Patients without heart failure and diseases mentioned in Exclusion Criteria.
- In our study cutoff levels for NT-pro BNP was
  1. >450 pg/ml for those aged < 50 years.
  2. >900 pg/ml for those aged 50-70 years.

a) Inclusion Criteria
1. Age 40-70 years.
2. Complains of sudden onset dyspnea suspected to be due to cardiac causes.
3. Patients who signed the written informed consent.
4. Patients who did not meet the exclusion criteria.

b) Exclusion Criteria
1. Cor pulmonale.
2. Sepsis.
3. Lung Cancer.
4. Pulmonary Embolism.
5. ARDS.
7. Renal failure.
8. Patients not willing to participate in the study.

III. Results
Comparison of mean NT-proBNP:

![Comparison of mean NT-proBNP](image_url)
Comparison of NT-proBNP among cases and controls:

Comparison of Mean NT-proBNP values by EF values among the study groups:
Comparison of NT-proBNP levels with NYHA grading:

Comparison of NT-ProBNP levels with NYHA grading

Comparison of EF Values:
IV. Discussion

- Among 30 controls:
  1. 29 had NT-proBNP levels within normal range for their age.
  2. 1 had elevated level of NT-ProBNP for their age.

- Among 30 cases:
  3. 24 had NT-ProBNP level elevated for their age and were diagnosed to have congestive cardiac failure.
  4. 6 had NT-ProBNP levels within normal limits for their age. These 6 patients had a normal 2D-ECHO. Breathlessness in these patients was due to non cardiac cause.
V. Discussion

- The mean value of NT-proBNP raises with decreasing EF. NT-ProBNP values have an inverse relationship with EF values. There was a strong correlation between the 2 variables with a p value of <0.001.
- There is a raise in NT-proBNP value with increasing NYHA grades. There was a significant correlation between the 2 variables with a 'P' value of 0.049.
- The mean NT-ProBNP Value among controls was 568.43 pg/ml. The mean NT-proBNP value among cases as 8253.13pg/ml. It was statistically significant with a 'P' value of <0.001.

VI. Conclusion

1. Serum NT-proBNP levels are significantly elevated in cases compared to controls making it a valuable diagnostic marker in Congestive Cardiac Failure.
2. Serum NT-proBNP levels correlate inversely with the EF levels.

Bibliography

4. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 2012; 14; 803-69.